CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Edoxaban

Last Updated: June 8, 2016
Result type: Reports
Project Number: SR0500-000
Product Line: Reimbursement Review

Generic Name: Edoxaban

Brand Name: Lixiana NVAF

Manufacturer: Daiichi Sankyo, Inc.

Indications: Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 21, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions